Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Top Cited Papers
- 12 August 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (16), 6779-6788
- https://doi.org/10.1158/0008-5472.can-08-0742
Abstract
Hepatocellular carcinomas represent the third leading cause of cancer-related deaths worldwide. The vast majority of cases arise in the context of chronic liver injury due to hepatitis B virus or hepatitis C virus infection. To identify genetic mechanisms of hepatocarcinogenesis, we characterized copy number alterations and gene expression profiles from the same set of tumors associated with hepatitis C virus. Most tumors harbored 1q gain, 8q gain, or 8p loss, with occasional alterations in 13 additional chromosome arms. In addition to amplifications at 11q13 in 6 of 103 tumors, 4 tumors harbored focal gains at 6p21 incorporating vascular endothelial growth factor A (VEGFA). Fluorescence in situ hybridization on an independent validation set of 210 tumors found 6p21 high-level gains in 14 tumors, as well as 2 tumors with 6p21 amplifications. Strikingly, this locus overlapped with copy gains in 4 of 371 lung adenocarcinomas. Overexpression of VEGFA via 6p21 gain in hepatocellular carcinomas suggested a novel, non–cell-autonomous mechanism of oncogene activation. Hierarchical clustering of gene expression among 91 of these tumors identified five classes, including “CTNNB1”, “proliferation”, “IFN-related”, a novel class defined by polysomy of chromosome 7, and an unannotated class. These class labels were further supported by molecular data; mutations in CTNNB1 were enriched in the “CTNNB1” class, whereas insulin-like growth factor I receptor and RPS6 phosphorylation were enriched in the “proliferation” class. The enrichment of signaling pathway alterations in gene expression classes provides insights on hepatocellular carcinoma pathogenesis. Furthermore, the prevalence of VEGFA high-level gains in multiple tumor types suggests indications for clinical trials of antiangiogenic therapies. [Cancer Res 2008;68(16):6779–88]Keywords
Other Versions
This publication has 51 references indexed in Scilit:
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Molecular targeted therapies in hepatocellular carcinomaHepatology, 2008
- Assessing the significance of chromosomal aberrations in cancer: Methodology and application to gliomaProceedings of the National Academy of Sciences of the United States of America, 2007
- Characterizing the cancer genome in lung adenocarcinomaNature, 2007
- Hepatocellular carcinoma pathogenesis: from genes to environmentNature Reviews Cancer, 2006
- Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic ApproachCell, 2006
- Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arraysOncogene, 2006
- GenePattern 2.0Nature Genetics, 2006
- Common markers of proliferationNature Reviews Cancer, 2006
- PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomasHepatology, 2003